Anti-neurofascin antibody in patients with combined central and peripheral demyelination.
about
B Cells and Autoantibodies in Multiple SclerosisNeuro-glial interactions at the nodes of Ranvier: implication in health and diseasesMapping autoantigen epitopes: molecular insights into autoantibody-associated disorders of the nervous systemNeurofascin IgG4 antibodies in CIDP associate with disabling tremor and poor response to IVIg.Role of the axonal initial segment in psychiatric disorders: function, dysfunction, and interventionThe Pathogenesis of the Demyelinating Form of Guillain-Barre Syndrome (GBS): Proteo-peptidomic and Immunological Profiling of Physiological Fluids.Chronic inflammatory demyelinating polyradiculoneuropathy: from pathology to phenotype.Characterization of IgG4 anti-neurofascin 155 antibody-positive polyneuropathy.Neurofascin-155 IgG4 in chronic inflammatory demyelinating polyneuropathy.Neurofascin-155 as a putative antigen in combined central and peripheral demyelinationNeurofilament light chain level is a weak risk factor for the development of MS.Central Nervous System Demyelination in a Charcot-Marie-Tooth Type 1A Patient.To look for a needle in a haystack: the search for autoantibodies in multiple sclerosis.Chronic inflammatory demyelinating polyradiculoneuropathy and variants: where we are and where we should go.Autoimmune antigenic targets at the node of Ranvier in demyelinating disorders.Fulminant Central Plus Peripheral Nervous System Demyelination without Antibodies to Neurofascin.Diagnosis and therapy of acute disseminated encephalomyelitis and its variants.A rare association between multiple sclerosis and Charcot-Marie-Tooth type 1B.Autoantibodies in chronic inflammatory neuropathies: diagnostic and therapeutic implications.Anti-NF155 chronic inflammatory demyelinating polyradiculoneuropathy strongly associates to HLA-DRB15.Neurofascin (NF)155- and NF186-Specific T Cell Response in a Patient Developing a Central Pontocerebellar Demyelination after 10 Years of CIDP.Neurofascin antibodies in autoimmune, genetic, and idiopathic neuropathies.Shifting borders, crossing boundaries: The case of combined central and peripheral demyelination.Impairment of quality of life and cognition in demyelinating neuropathies: targets to be considered from diagnosis to treatment?A Patient With Encephalomyeloradiculoneuropathy Exhibiting a Relapsing-Remitting Clinical Course: Correlation of Serum and Cerebrospinal Fluid Anti-Neutral Glycosphingolipids Antibodies With Clinical Relapse.Devastating humoral CIDP variant remitted by autologous stem cell transplantation.Possible Combined Central and Peripheral Demyelination Presenting as Optic Neuritis, Cervical Myelitis, and Demyelinating Polyneuropathy with Marked Nerve Hypertrophy.Autoantibodies Against the Node of Ranvier in Seropositive Chronic Inflammatory Demyelinating Polyneuropathy: Diagnostic, Pathogenic, and Therapeutic Relevance.Diagnostic insights into chronic-inflammatory demyelinating polyneuropathiesAssociation of neurofascin IgG4 and atypical chronic inflammatory demyelinating polyneuropathy: A systematic review and meta-analysis
P2860
Q26801386-16C93A83-0E93-432A-B6DD-7E3BBA7B43D9Q26825224-29CA318E-C38F-400F-AD44-747884938C2DQ28075974-83D5D46D-48A2-4F7F-B537-933B0F8F907EQ30574385-912DC55C-7087-443A-9FDB-41535A1B51F6Q34071914-380AD9BA-DB57-4CC6-95FD-A0955CC2B237Q34677183-9EC5CB45-FFD4-48A9-B8ED-5AAB4FEFCD72Q36005389-A79B630C-6BFE-4E3B-BDA6-C5D3B853BD7FQ36154796-8BEAEEF6-3810-44E3-BBFD-935CF85EC780Q36691991-13A22B67-8A10-42DD-BEDC-D4D90F40238DQ36981065-7B4BFF3E-D5DB-4024-9405-4D3C7F7CBB54Q37265143-F5E1B52A-D9EA-4927-89F3-CE75609155F3Q37423008-756B7956-602D-451A-B0AD-5D35667BFE57Q38192844-4CA0A7A6-5A52-41E5-85D7-87C75C443DA1Q38194642-E13F83EA-057C-46EC-B5FE-DE792E777C4DQ38333532-21CCAEEA-2D5D-4CC9-AC41-8118CFE29DFCQ38566269-D8DC530B-353D-4396-903D-3389F8D0766AQ38653606-53C51227-7FF9-4D86-9A00-E79561EA2318Q39329994-5B2A9F55-FB57-4B95-AB8B-DF41B0467120Q39434973-7CD133A8-0CD8-4DF1-8AF3-BF6CE6090A23Q46866734-1BF4C837-6362-4817-A73F-28172EAAC7FAQ47221782-EE97192A-944E-41F3-BA93-01B478B0FEE2Q47327481-0DB2351D-5ED6-4E4F-8D83-5101E209F627Q47670985-3F5DF789-8B19-47D2-A55F-48B44B1F34E3Q48081776-8D284A9B-C508-4895-84F2-61A343D12E8DQ52579206-04F477F5-FA0A-4867-8D1A-18506E28342EQ52855612-FB662325-7C02-40DA-936F-81F10CDE16EAQ55010646-D1CBFC36-1822-4C35-8E47-A31713008BFBQ55021064-9842F0C3-15E5-427C-A0EC-9C715265C61BQ57300562-42FFEC1F-D010-432E-A6A7-8B1F68626EC2Q58702983-0F0B2D6D-F60A-4C45-BFCC-F2F2D2DF4D8B
P2860
Anti-neurofascin antibody in patients with combined central and peripheral demyelination.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh-hant
name
Anti-neurofascin antibody in patients with combined central and peripheral demyelination.
@en
Anti-neurofascin antibody in patients with combined central and peripheral demyelination.
@nl
type
label
Anti-neurofascin antibody in patients with combined central and peripheral demyelination.
@en
Anti-neurofascin antibody in patients with combined central and peripheral demyelination.
@nl
prefLabel
Anti-neurofascin antibody in patients with combined central and peripheral demyelination.
@en
Anti-neurofascin antibody in patients with combined central and peripheral demyelination.
@nl
P2093
P1433
P1476
Anti-neurofascin antibody in patients with combined central and peripheral demyelination.
@en
P2093
Dai Matsuse
Hidenori Ogata
Hiroyuki Murai
Jun-Ichi Kira
Nobutoshi Kawamura
Ryo Yamasaki
Shigemi Nagayama
Takuya Matsushita
Tomomi Yonekawa
Yasuo Fukuda
P304
P356
10.1212/WNL.0B013E3182A1AA9C
P407
P577
2013-07-24T00:00:00Z